In the rapidly evolving world of healthspan and longevity, 2023 was a year defined not only by scientific discovery but by collaboration, capital, and community. The Longevity Investor Network (LIN), a mission-driven initiative connecting forward-thinking investors with transformative biotech and health companies, stood at the heart of that evolution.
As the year drew to a close, LIN’s momentum was unmistakable. It expanded its investor base, catalyzed funding for emerging companies, and laid the groundwork for deeper collaboration in 2024. Yet beyond the numbers lies something more powerful: a maturing ecosystem that understands aging not as an inevitable decline but as a challenge that can—and must—be solved.
This is the story of LIN in 2023: a community scaling up to meet the urgency of time.
Building Bridges Between Capital and Science
LIN began with a clear purpose: to make it easier for innovative longevity companies to find smart, committed capital. In practice, that means building trust between two often disconnected worlds—scientific discovery and strategic investment.
By the end of 2023, more than 200 investors had joined the network. This diverse group includes:
- Angel investors and high-net-worth individuals (60%)
- Venture capital funds (20%)
- Family offices (5%)
- Corporate venture arms (5%)
- Foundations and endowments (5%)
- Other funding institutions (5%)
While early efforts focused heavily on angel investors, 2023 marked a turning point. LIN began to deepen relationships with institutional funders, signaling a readiness to bring larger checks, more structured partnerships, and a broader worldview into the longevity conversation.
This strategic pivot isn’t just about money—it’s about diversifying the types of support available to startups navigating a complex, multidisciplinary path from lab to market.
A Year of Entrepreneurial Energy: 40 Longevity Companies, One Bold Vision
On the other side of the table, LIN also expanded its support for founders. In 2023 alone, 40 longevity-focused companies presented their innovations to the network . These startups represent the leading edge of anti-aging and regenerative medicine, tackling problems from multiple biological and technological angles.
Key focus areas included:
- Neurodegeneration (5 companies)
- Partial cellular reprogramming, gene and stem cell therapies (5)
- Science-backed supplements (4)
- Tissue regeneration and preservation (4)
- Mitochondrial dysfunction, protein crosslinking, and extracellular matrix health (3)
- Senescence-targeted therapies (3)
- Cardiometabolic aging (3)
- Cryopreservation and organ/tissue banking (3)
- Parabiosis and blood factors (2)
- Dermatologic aging (1)
- Reproductive aging (1)
- Computational biology (1)
- Medical devices and wellness protocols (2)
- Metastasis resistance and oncology (1)
- Media and educational platforms (1)
What’s striking isn’t just the variety—it’s the maturity. Many of these companies are building on strong scientific foundations, tackling difficult areas like neurodegeneration and gene delivery with approaches that blend ambition with rigor.
And thanks to LIN, they’re increasingly able to do so with the capital and coaching they need to scale.
Tangible Outcomes: Over $4.4 Million Raised (And Counting)
Numbers don’t tell the whole story—but in a space like longevity, they matter.
Companies that pitched to LIN investors in 2023 raised over $1.9 million by year’s end, with that figure expected to exceed $2 million once outstanding diligence processes close . Since LIN’s inception, the total capital facilitated by the network has now surpassed $4.4 million, directly funding startups aimed at extending human healthspan.
That’s meaningful progress—and it’s accelerating.
Importantly, these funds aren’t being sprinkled thinly across buzzwords. They’re being deployed into companies with concrete data, executable roadmaps, and an understanding that aging is not just a medical condition but a systems-level failure we can address through science.
Growing the Infrastructure for Smarter Capital
Beyond deal flow, 2023 was about creating the infrastructure to support better decisions, deeper connections, and more transparent capital movement.
New initiatives that gained traction in Q4 included:
- A dedicated Slack community to foster investor engagement and dialogue
- Improved systems to track capital deployment and portfolio company performance
- Fundraising support and coaching tailored for longevity entrepreneurs
- A professional-facing LinkedIn page and group to facilitate networking and updates
These tools may seem mundane—but in a nascent space, they’re crucial. They make it easier for the right people to find each other, share insights, and move faster.
And speed, in longevity, is not a luxury. It’s everything.
Looking Ahead: 2024 and Beyond
The groundwork laid in 2023 is already shaping a bolder vision for the year ahead.
In 2024, LIN aims to:
- Expand its community of institutional investors while continuing to serve its core base of angel backers
- Accelerate partnerships with research foundations and policy leaders
- Launch new educational programs to help investors understand emerging longevity modalities—from senolytics to epigenetic reprogramming
- Support cohort-based investment opportunities, where multiple aligned investors can syndicate capital around promising companies
- Deepen relationships with founders, not just through capital but strategic guidance and platform support
It’s an evolution from network to ecosystem—a recognition that real change requires not just capital, but alignment, infrastructure, and shared commitment.
Why LIN Matters: Bridging the Science–Finance Divide
Why does any of this matter for wellness, longevity, and the broader goal of healthier, longer lives?
Because the breakthroughs we’re hoping for—disease-delaying therapeutics, regenerative biologics, healthspan-enhancing interventions—won’t make it to the public without well-funded, well-connected founders.
Aging biology is one of the most capital-intensive, regulation-heavy, and slow-to-monetize fields in biotech. It’s also one of the most consequential.
LIN serves as a vital translator and bridge between two essential camps:
- Scientists and entrepreneurs with the vision and technical knowledge to tackle aging
- Investors and philanthropists with the resources and strategic experience to turn vision into reality
By helping both speak the same language and build mutual trust, LIN is creating the conditions for long-term success—not just for its members, but for everyone who stands to benefit from longer, healthier lives.
Final Reflections: Investing in a Longer Future
The Longevity Investor Network isn’t just a funding group. It’s a movement of belief—in the capacity of science to reshape what aging looks like, and in the necessity of smart, compassionate capital to drive that change.
Its members aren’t speculators chasing trends. They’re builders of the future, backing the companies that will one day help our children—and maybe even ourselves—live not just longer, but better.
2023 was a year of momentum. 2024 is poised to be a year of acceleration.
If you’re an investor looking to align your capital with impact, or a founder building the future of healthspan, now is the time to engage.
As the network’s team put it best: “We are still early. But we are no longer alone.”